Volitionrx Ltd Market Cap ($18.20 Million)
Market Cap & Net Worth: Volitionrx Ltd (VNRX)
Volitionrx Ltd market cap. Volitionrx Ltd (NYSE MKT:VNRX) has a market capitalization of $18.20 Million ($18.20 Million) as of November 3, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #25259 globally and #5361 in its home market, demonstrating a 42.27% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Volitionrx Ltd's stock price $3.13 by its total outstanding shares 8087955 (8.09 Million). Also see VNRX operating cash flow for how efficiently the company converts equity into cash flow.
Volitionrx Ltd Market Cap History (2015–2026)
Volitionrx Ltd market cap history from 2015 to 2026. Data shows change from $36.40 Million to $25.32 Million (-3.69% CAGR). Check Volitionrx Ltd stock quote for real-time trading data and today's change.
Volitionrx Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Volitionrx Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Volitionrx Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.20x
Volitionrx Ltd's market cap is 1.20 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $38.34 Million | $17.10K | -$16.10 Million | 2242.45x | N/A |
| 2020 | $31.46 Million | $13.43K | -$20.35 Million | 2342.15x | N/A |
| 2021 | $25.40 Million | $90.03K | -$26.81 Million | 282.07x | N/A |
| 2022 | $19.65 Million | $306.39K | -$30.27 Million | 64.15x | N/A |
| 2023 | $5.80 Million | $775.30K | -$35.32 Million | 7.48x | N/A |
| 2024 | $4.85 Million | $1.23 Million | -$26.97 Million | 3.93x | N/A |
| 2025 | $2.07 Million | $1.73 Million | -$23.36 Million | 1.20x | N/A |
Competitor Companies of VNRX by Market Capitalization
Companies near Volitionrx Ltd in the global market cap rankings as of November 3, 2026. Also see VNRX total asset value for a full breakdown of the balance sheet.
Key companies related to Volitionrx Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #110 globally with a market cap of $191.55 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #204 globally with a market cap of $117.68 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #227 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #110 | Abbott Laboratories | NYSE:ABT | $191.55 Billion | $110.16 |
| #204 | Stryker Corporation | NYSE:SYK | $117.68 Billion | $306.81 |
| #227 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $99.29 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Volitionrx Ltd (2015–2026)
Market capitalization of Volitionrx Ltd from 2015 to today. Between 2015 and today, Volitionrx Ltd's market cap moved from $36.40 Million to $ 25.32 Million, with a yearly change of -3.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $25.32 Million | +1124.57% |
| 2025 | $2.07 Million | -57.40% |
| 2024 | $4.85 Million | -16.32% |
| 2023 | $5.80 Million | -70.49% |
| 2022 | $19.65 Million | -22.61% |
| 2021 | $25.40 Million | -19.28% |
| 2020 | $31.46 Million | -17.93% |
| 2019 | $38.34 Million | +161.88% |
| 2018 | $14.64 Million | -38.44% |
| 2017 | $23.78 Million | -35.67% |
| 2016 | $36.96 Million | +1.56% |
| 2015 | $36.40 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Volitionrx Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.20 Million USD |
| MoneyControl | $18.20 Million USD |
| MarketWatch | $18.20 Million USD |
| marketcap.company | $18.20 Million USD |
| Reuters | $18.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Volitionrx Ltd
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleos… Read more